HOME > About Us > Our History

RIBOMIC, Inc. is a leading company in the world developing innovative aptamer therapeutics.

Our History

Year Month Corporate Our History
2003 August Founded at 3-27 Nakadai, Itabashi-ku, Tokyo (Capital JPY 10 million) with the primary startup business of pharmaceutical consultation.
2005 March The head office was moved to 3-15-5 Shirokanedai, Minato-ku, Tokyo, and full-fledged therapeutic aptamer business was initiated.
2005 April Entered into the research and development consignment agreement with National Institute of Biomedical Innovation (NIBI) on the aptamer-based cancer therapy.
2005 June Entered into the multi-year cooperative research contract with The University of Tokyo (UTokyo) on aptamer therapeutics, and started the research laboratory in the Crest Hall, Institute of Medical Science.
2005 October Entered into the research and development consignment agreement with Japan Science and Technology Agency (JST) on the multi-target development of RNA-based ‘nanosensors’ and ‘modulators’.
2005 November Opened the Therapeutic RNA Aptamer Institute at Shirokanedai, Minato-ku, Tokyo.
2006 October Entered into research and development consignment agreement with Japan Science and Technology Agency (JST) on "JST Innovation Bridge”.
2006 October Entered into the non-exclusive license agreement with Archemix Corp. (USA) on the use of the SELEX patents focused on the IgG aptamer.
2007 August The head office was moved to 3-16-13 Shirokanedai, Minato-ku, Tokyo.
2007 August Entered into the research and development consignment agreement with The National Institute of Biomedical Innovation (NIBIO) on the drug and medical device implementation support program.
2007 December Entered into the exclusive license agreement with Archemix Corp. (USA) on the use of the SELEX patents focused on the midkine aptamer.
2008 January Entered into the long-term collaborative research agreement with Otsuka Pharmaceutical Co., Ltd. for the development and marketing of RNA aptamer pharmaceuticals.
2008 June Entered into the exclusive license agreement with Archemix Corp. (USA) on the research licensing options.
2011 February Entered into the agreement on the technical advice of RNA aptamer drug discovery with Zenyaku Kogyo Co., Ltd.
2011 August The New Energy and Industrial Technology Development Organization (NEDO) accepted and granted RIBOMIC’s proposal of the development of novel therapeutic RNA aptamers for intractable diseases associated with chronic inflammation as part of the government innovation programs.
2012 April Installed the donation laboratory “RNA Medical Science” in UTokyo Institute of Medical Science based on a multi-year cooperative research contract.
2013 April The New Energy and Industrial Technology Development Organization (NEDO) accepted and granted RIBOMIC’s proposal of the development of therapeutic RNA aptamers for refractory inflammatory diseases.
2014 March Entered into the multi-year cooperative research agreement with Taisho Pharmaceutical Co., Ltd. on the therapeutic aptamer discovery.
2014 April Entered into the exclusive worldwide license agreement with Fujimoto Pharmaceutical Corporation for the anti-NGF aptamer.
2014 September Listed in the Tokyo Stock Exchange market Mothers (code: 4591).